Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of young children, as well as for improving immunity and bad breath; BLIS M18, an oral probiotic to support teeth, gums, and dental health; and BLIS Q24, a probiotic supplement to balance and restore the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Buy
Sell